2026-06-14T05:05:20Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/92872024-09-27T09:34:22Zcom_20.500.12105_19604com_20.500.12105_2051col_20.500.12105_19605

00925njm 22002777a 4500 dc Yin, Xiaoyan author Willinger, Christine M author Keefe, Joshua author Liu, Jun author Fernandez-Ortiz, Antonio author Ibáñez, Borja author Peñalvo, Jose L author Adourian, Aram author Chen, George author Corella, Dolores author Pamplona, Reinald author Portero-Otin, Manuel author Jove, Mariona author Courchesne, Paul author van Duijn, Cornelia M author Fuster, Valentin author Ordovas, Jose M author Demirkan, Ayşe author Larson, Martin G author Levy, Daniel author 2020-01 BACKGROUND: Metabolic syndrome (MetS), the clustering of metabolic risk factors, is associated with cardiovascular disease risk. We sought to determine if dysregulation of the lipidome may contribute to metabolic risk factors. METHODS: We measured 154 circulating lipid species in 658 participants from the Framingham Heart Study (FHS) using liquid chromatography-tandem mass spectrometry and tested for associations with obesity, dysglycemia, and dyslipidemia. Independent external validation was sought in three independent cohorts. Follow-up data from the FHS were used to test for lipid metabolites associated with longitudinal changes in metabolic risk factors. RESULTS: Thirty-nine lipids were associated with obesity and eight with dysglycemia in the FHS. Of 32 lipids that were available for replication for obesity and six for dyslipidemia, 28 (88%) replicated for obesity and five (83%) for dysglycemia. Four lipids were associated with longitudinal changes in body mass index and four were associated with changes in fasting blood glucose in the FHS. CONCLUSIONS: We identified and replicated several novel lipid biomarkers of key metabolic traits. The lipid moieties identified in this study are involved in biological pathways of metabolic risk and can be explored for prognostic and therapeutic utility. EBioMedicine. 2020; 51:102520 10.1016/j.ebiom.2019.10.046 2352-3964 23523964 EBioMedicine 31877415 http://hdl.handle.net/20.500.12105/9287 Biomarker Cardiovascular disease Dysglycemia Dyslipidemia Metabolic risk Metabolic syndrome Lipidomic profiling identifies signatures of metabolic risk